PR Newswire Clinical TrialsOriginal article
Sensorium Therapeutics Announces SNTX-2643 Phase 1a Data to Be Presented at Psych Congress 2026
Phase 1SNTX-2643Neutral
AI Analysis
Summary
Sensorium Therapeutics announced Phase 1a clinical data for SNTX-2643, a small-molecule CNS therapeutic candidate, will be presented at Psych Congress 2026. The article provides no detail on data outcomes or specific results.
Clinical Trial Data
Phase
1a
Importance:4/10
Sentiment:
0.00
CNSsmall-moleculePhase 1apsychiatric disordersneurological disordersdata presentation
Read the original article
Published by PR Newswire Clinical Trials on August 19, 2026 1:41 PM